Complement-Based Drug Development Summit leaderboard
  • Thursday, October 1, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

17th World ADC San Diego Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 33

Author

Pharma Journalist 9091 posts 0 comments

Novo Nordisk Launches Oral Ozempic for Type 2 Diabetes

May 4, 2026
Novo Nordisk has announced the U.S. launch of Ozempic® (semaglutide) tablets, marking a significant expansion of its blockbuster diabetes franchise by introducing an oral version of the…
Read More...

Australia Approves First FCS Treatment REDEMPLO by Arrowhead

May 4, 2026
Arrowhead Pharmaceuticals, Inc. has announced that Australia’s Therapeutic Goods Administration (TGA) has approved REDEMPLO® (plozasiran), marking the first authorized treatment in the…
Read More...

Gilead Completes $7.8 Billion Arcellx Acquisition Deal

Apr 29, 2026
Gilead Sciences has finalized its acquisition of Arcellx, completing a deal valued at approximately $7.8 billion. The transaction marks a strategic expansion of Gilead’s oncology…
Read More...

EU Approves Rhapsido for Chronic Hives Treatment

Apr 29, 2026
Novartis has secured approval from the European Commission for its novel therapy Rhapsido, marking a significant advancement in the treatment of chronic spontaneous urticaria (CSU). The…
Read More...

Lilly to Acquire Ajax in $2.3 Billion Deal

Apr 29, 2026
Eli Lilly and Company has announced a definitive agreement to acquire Ajax Therapeutics, a move aimed at strengthening its oncology pipeline with a next-generation treatment for blood…
Read More...

Saphnelo Pen Approval Expands Lupus Treatment Access

Apr 29, 2026
AstraZeneca has received approval from the U.S. Food and Drug Administration for a new self-administered version of its lupus treatment, Saphnelo, marking a significant step forward in…
Read More...

BioMarin Completes $4.8 Billion Amicus Acquisition

Apr 28, 2026
BioMarin Pharmaceutical Inc. has finalized its acquisition of Amicus Therapeutics in an all-cash deal valued at approximately $4.8 billion, marking a significant expansion of its rare…
Read More...

Sun Pharma to Acquire Organon in $11.75 Billion Deal

Apr 28, 2026
Sun Pharmaceutical Industries Limited has announced a landmark agreement to acquire Organon & Co. in an all-cash transaction valued at approximately $11.75 billion. Under the terms…
Read More...

Leinco, CellCarta Partner to Advance Proteomics in Oncology

Apr 24, 2026
Leinco Technologies and CellCarta have announced a strategic collaboration to enhance proteomics solutions aimed at supporting immuno-oncology research and the development of targeted…
Read More...

Cipla Wins US Approval for Generic Ventolin Inhaler

Apr 23, 2026
Cipla Limited and its wholly owned subsidiary Cipla USA Inc. have secured final approval from the U.S. Food and Drug Administration (USFDA) for their Abbreviated New Drug Application…
Read More...
Prev Next
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Microbiome Movement USA Summit 2026
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Biomarker Operations & Biospecimen Management
2nd Obesity & Weight Loss Drug Development Summit Europe
RNA-Based Therapeutics & Vaccines Summit South Korea
RNA-Targeted Drug Discovery & Development Summit
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
10th IPF Summit
17th World ADC London
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
Model-Informed Drug Development Summit 2026
IMPACCT Real-World Evidence Summit
Raw Materials for Cell & Gene Therapy Summit
10th Dermatology Drug Development Summit
9th Lab Asset & Facility Management Summit
Covalent Drug Discovery & Development Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
17th World ADC San Diego
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Semaglutide 2 mg Linked to Lower Cardiovascular Risk in Diabetes
  • Novo Nordisk Licenses HRS-1596 for Weekly Oral GLP-1 Therapy
  • AbbVie’s Juvmo Wins FDA Approval for Parkinson’s Disease
  • Tolerance Bio Licenses TLB-33 to Expand Thymic Health Pipeline
  • Direct RNA Binding Emerges as a Powerful Approach for Functional Disease Modulation

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Direct RNA Binding Emerges as a Powerful Approach for…

AI, Structure Prediction and Advanced Computational Tools…

New Preclinical Data and Translational Advances Set to Take…

FDA, Health Canada & Leading Biopharma Organizations…

Industry Leaders Convene in Boston as Registration Remains…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.